The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience

Cover Page

Cite item

Full Text

Abstract

Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials and methods. We analyzed the combined Russian experience of eribulin application in BC patients associated with brain metastases; the analysis included 459 Russian women with advanced BC who had received at least 2 course of eribulin during the period from 2014 to 2018; 35 of 459 patients had brain metastases (40.0% - luminal HER2-negative subtype, 31.4% - triple negative subtype and 28.6%h - HER2-positive BC). The median age was 52 years (39 - 80 years of age). In most cases, the patient had two or more metastatic brain lesions (68.6%; the median was - 3); brain radiotherapy was used in 62.8% of patients before eribulin treatment and in 5.8% of patients was held stereotactic radiation therapy during eribulin chemotherapy. We analyzed the efficiency of eribulin application (the therapy continued until disease progression, the development of unacceptable toxicity, or impossibility to apply the drug for any other reason). Results. The results showed that clinical efficacy (objective response rate + stabilization of disease lasting for more than 6 months) was 48.6%: partial response - in 20% of patients and stabilization of disease - 62.9%; tumor growth control was in 82.9%. Median PFS in all group of patients with brain metastases was 4.1 months and was similar to median PFS in patients who received radiotherapy before eribulin treatment or without eribulin - 4.1 vs 3.47 months; p=0.798. Conclusions. The application of eribulin in BC patients with brain metastasis are absolutely justified, the drug demonstrates the efficiency in a retrospective analysis in a Russian population. The determination of the optimal algorithm for the treatment of patients with metastatic BC associated with brain metastasis requires a multidisciplinary approach and further research.

About the authors

Irina V Kolyadina

N.N. Blokhin National Medical Research Center of Oncology

Email: irinakolyadina@yandex.ru
D. Sci. (Med.), Prof.

Irina S Bulavina

Sverdlovsk Regional Oncology Center

Branch manager

Vladislav V Petkau

Sverdlovsk Regional Oncology Center

Head of the Center

Natalia V Strakhova

Sverdlovsk Regional Oncology Center

Branch manager

Vera A Gorbunova

N.N. Blokhin National Medical Research Center of Oncology

D. Sci. (Med.), Full Prof.

Elena I Kovalenko

N.N. Blokhin National Medical Research Center of Oncology

Cand. Sci. (Med.)

Liudmila V Manziuk

N.N. Blokhin National Medical Research Center of Oncology

D. Sci. (Med.), Full Prof.

Elena V Artamonova

N.N. Blokhin National Medical Research Center of Oncology

D. Sci. (Med.)

Liudmila G Zhukova

A.S. Loginov Moscow Clinical Scientific Practical Center

D. Sci. (Med.), Prof. of RAS

Larisa V Bolotina

P.A. Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological Center

D. Sci. (Med.)

Inna P Gan'shina

N.N. Blokhin National Medical Research Center of Oncology

Cand. Sci. (Med.)

Tatiana Iu Semiglazova

N.N. Petrov National Medical Research Center of Oncology

D. Sci. (Med.), Full Prof.

Aleksei G Manikhas

City Clinical Oncology Dispensary

D. Sci. (Med.)

Natalia A Raevskaia

City Clinical Oncology Dispensary

Branch manager

Ilia M Itkin

City Clinical Oncology Dispensary

Cand. Sci. (Med.)

Svetlana V Khokhlova

V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology

D. Sci. (Med.)

Dmitrii V Filonenko

Moscow City Oncology Hospital №62

Cand. Sci. (Med.)

Viktor E Gol'dberg

Research Institute of Oncology of the Tomsk National Research Medical Center

D. Sci. (Med.), Full Prof.

Natalia O Popova

Research Institute of Oncology of the Tomsk National Research Medical Center

Cand. Sci. (Med.)

Dmitrii M Ponomarenko

Regional Oncology Dispensary

Cand. Sci. (Med.)

Valentina E Shikina

Moscow Regional Oncological Dispensary

Branch manager

Liubov I Vladimirova

Rostov Research Institute of Oncology

D. Sci. (Med.), Full Prof.

Natalia M Tikhanovskaia

Rostov Research Institute of Oncology

chemotherapist

Elena V Karabina

Tula Regional Oncologic Dispensary

Branch manager

Guzel Z Mukhametshina

Republican Clinical Oncology Dispensary

Cand. Sci. (Med.)

Alfiia I Khasanova

Republican Clinical Oncology Dispensary

Cand. Sci. (Med.)

Sufiia Z Safina

Republican Clinical Oncology Dispensary

Cand. Sci. (Med.)

Mikhail V Shaidorov

Tolyatti City Clinical Hospital №5

Cand. Sci. (Med.)

Andrei E Orlov

Samara Regional Clinical Oncology Dispensary

D. Sci. (Med.)

Iuliia V Kostalanova

Samara Regional Clinical Oncology Dispensary

Cand. Sci. (Med.)

Natalia V Levchenko

Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)

Cand. Sci. (Med.)

Mikhail A Osipov

Leningrad Regional Oncological Dispensary

Cand. Sci. (Med.)

Tatiana V Karandeeva

D.D. Pletnev City Clinical Hospital

oncologist

Irina V Evstigneeva

Tver Regional Clinical Oncology Dispensary

Branch manager

Igor S Chernov

Oncologic Dispensary №5

Cand. Sci. (Med.)

Dzheims Dzh Kolokolov

City Polyclinic №195

oncologist

Anton Iu Povyshev

District Clinical Hospital

chemotherapist

Alina S Shatokhina

Clinical Oncology Center №1

Branch manager

Elena M Cherniakova

Republican Oncology Center

Branch manager

Oksana N Shkodenko

Stavropol Regional Clinical Oncology Dispensary

Branch manager

Evgeniia S Kuz'mina

Salekhard District Clinical Hospital

oncologist

References

  1. GLOBOCAN 2018; IACR, WHO, 2018; http://gco.iarc.fr/today
  2. Колядина И.В., Поддубная И.В. Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы. Современная Онкология. 2018; 20 (3): 26-9. doi: 10.26442/1815-1434_2018.3.26-29
  3. Колядина И.В., Поддубная И.В. Современные возможности терапии HER2-положительного рака молочной железы (по материалам клинических исследований). Современная Онкология. 2014; 16 (4): 10-20.
  4. Колядина И.В., Андреева Ю.Ю., Франк Г.А., Поддубная И.В. Роль биологической гетерогенности при рецидивирующем и метастатическом раке молочной железы. Архив патологии. 2018; 80 (6): 62-7.
  5. San-Gang Wu, Hui Li, Li-Ying Tang et al. The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. https://doi.org/10.1177/1010428317705082.
  6. Rostami R, Mittal S, Rostami P et al. Brain metastasis in breast cancer: A comprehensive literature review. J Neurooncol 2016; 127: 407-14.
  7. Lin N.U. Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience 2013; 7: 307.
  8. Arslan U.Y, Oksuzoglu B, Aksoy S et al. Breast cancer subtypes and outcomes of central nervous system metastases. Breast 2011; 20: 562-7.
  9. Altundag K, Bondy M.L, Mirza N.Q et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer 2007; 110: 2640-7.
  10. Arvold N.D, Oh K.S, Niemierko A et al. Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 2012; 136: 153-60. doi: 10.1007/s10549-012-2243-x
  11. Pestalozzi B.C, Zahrieh D, Price K.N et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 2006; 17: 935-44.
  12. Rades D, Lohynska R, Veninga T et al. Evaluation of 2 whole-brain radiotherapy schedules and prognostic factors for brain metastases in breast cancer patients. Cancer 2007; 110: 2587-92.
  13. Oehrlich N.E, Spineli L.M, Papendorf F, Park-Simon T-W. Clinical outcome of brain metastases differs significantly among breast cancer subtypes. Oncology Letters 2017; 14: 194-200.
  14. Li R, Zhang K, Siegal G.P, Shi Wei. Clinicopathological factors associated with survival in patients with breast cancer brain metastasis. Hum Pathol 2017; 64: 53-60.
  15. Priedigkeit N, Hartmaier R.J, Chen Y, Vareslija D. Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases JAMA Oncol 2017; 3 (5): 666-71. doi: 10.1001/jamaoncol.2016.5630
  16. Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management Authors: N.U. Lin, L.E. Gaspar, FASTRO, FACR, MBA, R. Soffietti.
  17. Bachelot T, Romieu G, Campone M. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14 (1): 64-71. doi: 10.1016/S1470-2045 (12)70432-1
  18. Hurvitz S, Singh R, Adams B. Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09). Ther Adv Med Oncol 2018; 10: 1758835918807339. doi: 10.1177/1758835918807339
  19. Fabi A, Alesini D, Valle E et al. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. Breast 2018; 41: 137-43. doi: 10.1016/j.breast.2018.07.004
  20. Petrelli F, Ghidini M, Lonati V et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. Eur J Cancer 2017; 84: 141-8. doi: 10.1016/j.ejca.2017.07.024
  21. Jacot W, Pons E, Frenel J.S et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat 2016; 157 (2): 307-18. doi: 10.1007/s10549-016-3828-6
  22. Uncu D, Bayoglu I.V, Arslan UY Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study. Asian Pac J Cancer Prev 2015; 16 (9): 4127-31.
  23. Linot B, Campone M, Augereau P et al. Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 2014; 117 (2): 253-9. doi: 10.1007/s11060-014-1378-5
  24. Erten C, Demir L, Somali I et al. Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013; 14 (6): 3711-7.
  25. Addeo R, Sperlongano P, Montella L et al. Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. Cancer Chemother Pharmacol 2012; 70 (4): 603-9.
  26. Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. Br J Cancer 2010; 102 (6): 995-1002. doi: 10.1038/sj.bjc.6605586
  27. Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377: 914-23.
  28. Chang A.Y, Ying X.X. Brain metastases from breast cancer and response to treatment with eribulin: a case series. Breast Cancer (Auck. l) 2015; 9: 19-24. J Clin Oncol 2015.
  29. Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348-54.
  30. Ekenel M, Hormigo A.M, Peak S et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 2007; 85: 223-7.
  31. Rosner D, Nemoto T, Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986; 58: 832-9.
  32. Caraglia M, Addeo R, Costanzo R et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57: 34-9.
  33. Linot B, Campone M, Augereau P et al. Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol 2014; 117: 253-9.
  34. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85: 1599-605.
  35. Cocconi G, Lottici R, Bisagni G et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 1990; 8: 327-34.
  36. Christodoulou C, Bafaloukos D, Linardou H et al; Hellenic Cooperative Oncology Group. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol 2005; 71: 61-5.
  37. Болотина Л.В., Манзюк Л.В., Горбунова В.А. и др. Результаты первого ретроспективного анализа данных по применению эрибулина у пациентов с метастатическим раком молочной железы в условиях реальной клинической практики в России. Современная Онкология. 2016; 18 (3): 27-32.
  38. Манзюк Л.В., Коваленко Е.И., Горбунова В.А. и др. Эффективность и безопасность эрибулина при различных подтипах рака молочной железы: данные из реальной клинической практики в России. Злокачественные опухоли. 2017; 7 (3): 46-56.
  39. Горбунова В.A., Koлядина И.В., Koваленко E.И. и др. Эффективность и безопасность эрибулина при HER2-отрицательном метастатическом раке молочной железы: данные многолетнего опыта из реальной клинической практики в России. Современная Онкология. 2019; 21 (1): 12-23.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies